VC-backed Blend Therapeutics appoints Fromkin as president and CEO
Watertown, Massachusetts-based Blend Therapeutics Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has named Drew Fromkin as president, CEO and a member of the company’s board of directors. Previously, Fromkin worked at Clinical Data Inc where he served as President and CEO. Blend Therapeutics' backers include Eminent Venture Capital, Flagship Ventures, NanoDimension and New Enterprise Associates.
13 April 2015•5 mins read
